Docetaxel en cáncer de mama metastásico multitratado

Introduction

Docetaxel every 15 days could be an option for patients with progression after already having therapy with three treatment lines, since it may be safe and effective in advanced, elderly, and fragile patients.

Objective

To demonstrate the efficacy and safety of docetaxel in patients with metastatic cancer and a background of chemotherapy treatment with paclitaxel or docetaxel as adjuvants, as well as having presented with disease progression in a period of less than a year.

Material and methods

Women aged between 21 and 89 years old treated in the Centro Universitario Contra el Cáncer of the UANL in Monterrey NL, México, from 2013 to 2015. Variables considered were: age, menopausal status, hormone receptors status, over expression of HER2 neu, location of metastatic sites, performance status 0-3, and comorbidities.

Results

Only 16 patients were evaluable among the 19 patients meeting the inclusion criteria. Nine patients (35%) had a partial response, and seven patients had stable disease status. Median progression free survival was 5.2 months; 95% CI; 3.1-10.3 months.

Conclusions

Patients with relapsing disease within 2 years after previous therapy with taxanes benefited most, since they may receive taxanes again. The most important predictors for docetaxel efficacy were visceral metastases, and the duration of the disease free interval.